CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 62.11 CNY -8.12% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CanSino Biologics Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Change in Working Capital
-ÂĄ952.9m
CAGR 3-Years
-138%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Change in Working Capital
-ÂĄ332.3m
CAGR 3-Years
26%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Change in Working Capital
-ÂĄ1.1B
CAGR 3-Years
15%
CAGR 5-Years
-67%
CAGR 10-Years
-17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Change in Working Capital
-ÂĄ16.8B
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
-14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Change in Working Capital
-ÂĄ5B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
-7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Change in Working Capital
-ÂĄ1.1B
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
67.83 CNY
Undervaluation 8%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Change in Working Capital?
Change in Working Capital
-952.9m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Change in Working Capital amounts to -952.9m CNY.

What is CanSino Biologics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-138%

Over the last year, the Change in Working Capital growth was 4%. The average annual Change in Working Capital growth rates for CanSino Biologics Inc have been -138% over the past three years .

Back to Top